Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Literature DB >> 28456379

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Abstract

Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic, earning CAR therapy a special distinction in the selection of "cancer immunotherapy" by Science as the breakthrough of the year in 2013. CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences, and regulatory compliance-the central tenets of CAR therapy. Here, we review two of these foundations: the genetic engineering approaches and cell types to engineer.

Entities: Disease Gene

Keywords: CAR; T cells; genetic engineering; genome editing; immunotherapy; vectors

Mesh：

Substances：

Year: 2017 PMID： 28456379 PMCID： PMC5417838 DOI： 10.1016/j.ymthe.2017.03.034

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

154 in total

1. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells.

Authors: T Brocker
Journal: Blood Date: 2000-09-01 Impact factor: 22.113

2. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.

Authors: Johannes L Zakrzewski; Adam A Kochman; Sydney X Lu; Theis H Terwey; Theo D Kim; Vanessa M Hubbard; Stephanie J Muriglan; David Suh; Odette M Smith; Jeremy Grubin; Neel Patel; Andrew Chow; Javier Cabrera-Perez; Radhika Radhakrishnan; Adi Diab; Miguel-Angel Perales; Gabrielle Rizzuto; Ewa Menet; Eric G Pamer; Glen Heller; Juan Carlos Zúñiga-Pflücker; Onder Alpdogan; Marcel R M van den Brink
Journal: Nat Med Date: 2006-08-27 Impact factor: 53.440

3. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Michael Hudecek; Barbara Pender; Emily Robinson; Reed Hawkins; Colette Chaney; Sindhu Cherian; Xueyan Chen; Lorinda Soma; Brent Wood; Daniel Li; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal: Sci Transl Med Date: 2016-09-07 Impact factor: 17.956

Review 4. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases.

Authors: Shengdar Q Tsai; J Keith Joung
Journal: Nat Rev Genet Date: 2016-05 Impact factor: 53.242

5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal: Blood Date: 2010-07-28 Impact factor: 22.113

6. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors: L M Mansky; H M Temin
Journal: J Virol Date: 1995-08 Impact factor: 5.103

Review 7. CAR therapy: the CD19 paradigm.

Authors: Michel Sadelain
Journal: J Clin Invest Date: 2015-09-01 Impact factor: 14.808

8. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors: Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal: J Immunother Date: 2013-02 Impact factor: 4.456

Review 9. Allorecognition and the alloresponse: clinical implications.

Authors: B Afzali; R I Lechler; M P Hernandez-Fuentes
Journal: Tissue Antigens Date: 2007-06

10. Integration of murine leukemia virus DNA depends on mitosis.

Authors: T Roe; T C Reynolds; G Yu; P O Brown
Journal: EMBO J Date: 1993-05 Impact factor: 11.598

36 in total

1. Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.

Authors: Yasuyuki Arai; Uimook Choi; Cristina I Corsino; Sherry M Koontz; Masaki Tajima; Colin L Sweeney; Mary A Black; Steven A Feldman; Mary C Dinauer; Harry L Malech
Journal: Mol Ther Date: 2018-03-10 Impact factor: 11.454

2. NOTCH Activation at the Hematovascular Mesoderm Stage Facilitates Efficient Generation of T Cells with High Proliferation Potential from Human Pluripotent Stem Cells.

Authors: Akhilesh Kumar; Jeong Hee Lee; Kran Suknuntha; Saritha S D'Souza; Abir S Thakur; Igor I Slukvin
Journal: J Immunol Date: 2018-12-21 Impact factor: 5.422

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

1. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells.

2. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.

3. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Review 4. Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases.

5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

6. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Review 7. CAR therapy: the CD19 paradigm.

8. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Review 9. Allorecognition and the alloresponse: clinical implications.

10. Integration of murine leukemia virus DNA depends on mitosis.

1. Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.

2. NOTCH Activation at the Hematovascular Mesoderm Stage Facilitates Efficient Generation of T Cells with High Proliferation Potential from Human Pluripotent Stem Cells.

Review 3. The dawn of vaccines for cancer prevention.

4. Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Review 5. Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.

6. Towards 'off-the-shelf' genetically modified T cells: prolonging functional engraftment in mice by CD8 veto T cells.

7. Next-generation cell therapies: the emerging role of CAR-NK cells.

8. Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma.

Review 9. Posttransplant chimeric antigen receptor therapy.

Review 10. Next-generation cell therapies: the emerging role of CAR-NK cells.